General Information
BounceWatch is an independent company data service, not affiliated with Optinose. To contact Optinose, visit optinose.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Optinose compare?
A PDF of Optinose and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Optinose soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Optinose on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Optinose
Business keywords: pharmaceutical industry, ENT specialists, chronic rhinosinusitis, nasal polyps, FDA approval, Exhalation Delivery System, clinical trials, sNDA submission, drug therapy, employee management, company culture
Funding Rounds & Investors (10)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $55.00M | 2 |
Nantahala Capital Management, D. E. Shaw & Co.
|
09 May 2024 |
| Post IPO Equity | $50.00M | - |
|
21 Nov 2022 |
| Post IPO Debt | $150.00M | 1 |
Pharmakon Advisors
|
12 Sep 2020 |
| Post IPO Equity | $54.00M | - |
|
21 Nov 2019 |
| Post IPO Debt | $100.00M | 1 | 02 Jan 2018 | |
| Series D | $37.00M | 3 | 09 May 2017 | |
| Series C | $30.00M | 3 | 06 Oct 2015 | |
| Series C | $35.00M | 3 | 05 Aug 2014 | |
| Private Equity Round | $48.50M | 2 | 07 Jun 2010 | |
| Seed Round | kr6.70M | 1 |
Oxygen House
|
14 Dec 2002 |
Optinose Alternatives & Competitors
View All AlternativesSciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...
Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases
Enabling a better future for people with rare immune disorders
FAQ About Optinose
Source: BounceWatch company record for Optinose, https://www.bouncewatch.com/company/optinose, updated 29 December 2024. When citing, please name BounceWatch and link this page.